Treatment of pediatric mild persistent asthma with low-dose budesonide inhalation suspension vs. montelukast in China.

Both treatments provided acceptable overall asthma control in children with mild persistent asthma; however, more reliever medication and more medical expenditures attributable to asthma were needed for BIS vs. montelukast in real-world settings, where factors such as compliance were also taken into account.